NCT06643507 Evaluation of the Modified VISTA Technique Using ALB-PRF vs CTG in the Treatment of Multiple Miller Class III Recessions
| NCT ID | NCT06643507 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Cairo University |
| Condition | Gingival Recession |
| Study Type | INTERVENTIONAL |
| Enrollment | 26 participants |
| Start Date | 2025-04-20 |
| Primary Completion | 2026-12-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 26 participants in total. It began in 2025-04-20 with a primary completion date of 2026-12-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
treatment of miller class III RT2 gingival recession using modified vista technique using connective tissue graft vs albumin PRF
Eligibility Criteria
Inclusion Criteria: * 18 years old good oral hygiene Exclusion Criteria: * smokers patients with poor oral hygiene
Contact & Investigator
Enji EA Ahmed, BDS.MDS.PHD
STUDY DIRECTOR
Cairo University
Frequently Asked Questions
Who can join the NCT06643507 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Gingival Recession. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06643507 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06643507 currently recruiting?
Yes, NCT06643507 is actively recruiting participants. Contact the research team at tamanni.mahmoud@dentistry.cu.edu.eg for enrollment information.
Where is the NCT06643507 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06643507 clinical trial?
NCT06643507 is sponsored by Cairo University. The principal investigator is Enji EA Ahmed, BDS.MDS.PHD at Cairo University. The trial plans to enroll 26 participants.